Literature DB >> 3334202

Tourette syndrome: recent advances.

G S Golden1.   

Abstract

In spite of new information relevant to the clinical and biological features of Tourette syndrome, areas of controversy still exist. A genetic substrate is present in at least some affected families; there also is clearly a genetic relationship between Tourette syndrome and chronic motor tic disorder. Patients with Tourette syndrome have an increased incidence of behavior problems, attention deficit disorder, and obsessive-compulsive symptoms. Treatment of the attention deficit disorder with psychostimulant drugs will exacerbate tics in some patients. Haloperidol remains the most consistently useful therapeutic agent. Pimozide and clonidine also may be useful, but further work is required before standard treatment protocols can be developed. The disorder most likely results from dysfunction of dopaminergic systems.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3334202     DOI: 10.1016/0887-8994(86)90045-7

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

1.  A case of bilateral self-induced keratoconus in a patient with tourette syndrome associated with compulsive eye rubbing: case report.

Authors:  Artemios Kandarakis; Michael Karampelas; Vasileios Soumplis; Christos Panos; Nikolaos Makris; Stylianos Kandarakis; Dimitrios Karagiannis
Journal:  BMC Ophthalmol       Date:  2011-09-21       Impact factor: 2.209

2.  Visual field defects detected in patients with Gilles de la Tourette syndrome: preliminary report.

Authors:  J M Enoch; A Itzhaki; V Lakshminarayanan; J P Comerford; M Lieberman
Journal:  Int Ophthalmol       Date:  1989-09       Impact factor: 2.031

3.  Corneal cross-linking for keratoconus caused by compulsive eye rubbing in patients with Tourette syndrome: Three case reports.

Authors:  Megumi Shinzawa; Naoko Kato; Kozue Kasai; Kenji Konomi; Yuzhu Chai; Jun Shimazaki
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.